Clinical trials: Sepsis, Severe
Sepsis, Respiratory Failure
Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
Patients with infections in their blood often become very sick. These patients are usually put in an intensive care unit for careful observation and treatment.
- Conditions
- Sepsis, Respiratory Failure, Agitation
- Trial name
- PRO-DEFENSE (NCT02203019)
- Testing
- Propofol, Dexmedetomidine, Fentanyl
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Texas Tech University Health Sciences Center
Septic Shock
Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
The investigators propose a dose finding study to determine the feasibility of Angiotensin II (AII) to increase mean arterial pressure in high-output shock.
- Trial name
- ATHOS (NCT01393782)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Washington University
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Sepsis
Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure.
- Trial name
- CRYSTMAS (NCT00464204)
- Testing
- 6 % Hydroxyethylstarch 130/0.4 = "Voluven®", 0.9 % NaCl
- Where
- 24 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Fresenius Kabi
Sepsis
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.
- Trial name
- NCT00089986
- Testing
- Intravenous GR270773- Phospholipid Emulsion
- Where
- 390 sites in United States, Argentina and 32 more
- Volunteers
- 1,415 people
- Sponsor
- GlaxoSmithKline
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
New Onset Atrial Fibrillation, Severe Sepsis
Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock
Purpose/Objectives: Severe sepsis and septic shock are a common cause of new onset atrial fibrillation (NOAF) in the intensive care unit. Development of NOAF in this setting can prolong length of stay and increase mortality.
- Conditions
- New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
- Trial name
- NCT02668432
- Testing
- Amiodarone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Severe Sepsis, Acute Lung Injury
Citrulline in Severe Sepsis
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or…
- Trial name
- NCT01474863
- Testing
- High Dose Citrulline, Low Dose Citrulline
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt University
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Severe Sepsis
Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
Cell-free hemoglobin can be measured in the plasma of patients with sickle cell anemia, hemodialysis, after red blood cell transfusion, and in patients with sepsis.
- Trial name
- ACROSS (NCT01739361)
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt University
Sepsis, Severe, Septic Shock
LIPIDS-P Trial Phase I/II Trial
Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also…
- Trial name
- LIPIDS-P (NCT03405870)
- Testing
- Smoflipid
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Florida
Sepsis, Severe Sepsis
Piperacillin PK Analysis in Severe Sepsis Patients
Antibiotic dosing in septic patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02569086
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Aarhus
Severe Sepsis With Septic Shock
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7B (Immune…
- Trial name
- IRIS-7-B (NCT02640807)
- Testing
- Interleukin-7
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revimmune
Multiple Organ Failure, Septic Shock
Early Metabolic Resuscitation for Septic Shock
This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock.
- Conditions
- Multiple Organ Failure, Septic Shock, Severe Sepsis
- Trial name
- NCT03895853
- Testing
- Best Practice, early metabolic resuscitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Sepsis, Septic Shock
Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock
Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality.
- Trial name
- MiCHO (NCT00535821)
- Testing
- Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Loma Linda University
Severe Sepsis, Coagulopathy
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- NCT01598831
- Testing
- ART-123
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 816 people
- Sponsor
- Asahi Kasei Pharma America Corporation
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
SIRS, Sepsis
NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock
The purpose of this study is to determine the course of NT-proBNP plasma concentrations in the context of confounding parameters in postoperative/posttraumatic critically ill patients with severe SIRS/sepsis and shock.
- Conditions
- SIRS, Sepsis, Shock, Critically Ill
- Trial name
- NICUPS (NCT00736723)
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- University of Ulm
Gram-Negative Bacterial Infections, Sepsis
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.
- Trial name
- NCT00490477
- Testing
- Polymyxin -B fiber hemoperfusion system
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Turin, Italy